Effect of antihemostatic agents on experimental tumor dissemination
- PMID: 11885023
- DOI: 10.1055/s-2002-20562
Effect of antihemostatic agents on experimental tumor dissemination
Abstract
There is now considerable evidence that the blood coagulation system plays an important role in the biology of malignant tumors. This evidence has been derived from a combination of clinical, biochemical, histological, and pharmacological observations that point to the possibility of favorably affecting the course of malignant disease with agents that interfere with blood coagulation pathways. For a number of years our laboratory has used experimental models of blood-borne metastasis to study the events that follow the introduction of procoagulant-bearing tumor cells into the circulating blood. This article summarizes our experience with these models, which suggests that intravascular coagulation is a necessary prelude to lung tumor formation and that interruption of coagulation pathways in various ways may be an effective antimetastatic strategy. We have shown that anticoagulation with commonly used agents such as unfractionated heparin and warfarin (Coumadin) prevent tumor formation by limiting the ability of tumor cells to be retained in the pulmonary microvasculature. Binding of fibrin-coated tumor cells to activated platelets is essential for this retention and, therefore, treatment with potent antiplatelet agents such as abciximab is also effective. The predominant tumor procoagulant is tissue factor (TF), and direct targeting of this protein with concanavalin A, monoclonal antibodies, and tissue factor pathway inhibitor (TFPI) has provided compelling evidence that TF is an important determinant of tumor seeding in these experimental models. Collectively, our data provide strong support for the concept that some form of anticoagulant therapy would be a useful adjunct to existing cancer treatments.
Similar articles
-
Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis.Methods Mol Biol. 2010;663:241-59. doi: 10.1007/978-1-60761-803-4_10. Methods Mol Biol. 2010. PMID: 20617422
-
The role of tissue factor pathway inhibitor in tumor growth and metastasis.Semin Thromb Hemost. 2007 Oct;33(7):643-52. doi: 10.1055/s-2007-991531. Semin Thromb Hemost. 2007. PMID: 18000790 Review.
-
[Development and dissemination of malignant tumors and hemostasis].Pathol Biol (Paris). 1982 Dec;30(10):861-7. Pathol Biol (Paris). 1982. PMID: 6760066 Review. French.
-
Hemostasis and malignancy.Semin Thromb Hemost. 1998;24(2):93-109. doi: 10.1055/s-2007-995829. Semin Thromb Hemost. 1998. PMID: 9579631 Review.
-
Coagulation activation by MC28 fibrosarcoma cells facilitates lung tumor formation.Thromb Haemost. 1995 Jan;73(1):59-65. Thromb Haemost. 1995. PMID: 7740497
Cited by
-
A recombinant adenovirus vector encoding the light chain of human coagulation factor VII and IgG1 Fc fragment to targeting tissue factor for colorectal cancer immunotherapy in the mouse model.J Cancer Res Clin Oncol. 2013 Jun;139(6):1015-23. doi: 10.1007/s00432-013-1417-1. Epub 2013 Mar 15. J Cancer Res Clin Oncol. 2013. PMID: 23494077
-
Deciphering the molecular basis of breast cancer metastasis with mouse models.Rev Endocr Metab Disord. 2007 Sep;8(3):199-213. doi: 10.1007/s11154-007-9041-5. Rev Endocr Metab Disord. 2007. PMID: 17657606 Review.
-
APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice.J Cell Biochem. 2008 Jul 1;104(4):1311-23. doi: 10.1002/jcb.21709. J Cell Biochem. 2008. PMID: 18260128 Free PMC article.
-
A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment.Blood. 2012 Oct 4;120(14):2889-98. doi: 10.1182/blood-2012-04-425207. Epub 2012 Aug 9. Blood. 2012. PMID: 22879538 Free PMC article.
-
A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancer.Clin Breast Cancer. 2013 Dec;13(6):409-15. doi: 10.1016/j.clbc.2013.08.006. Clin Breast Cancer. 2013. PMID: 24267729 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous